ArticleBMC neurology2026
Impact of non-motor symptoms on the quality of life of Parkinson's disease patients in a cohort of Senegalese patients.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-motor symptoms (NMS) are common in Parkinson's disease (PD). They contribute significantly to changes in patients' quality of life (QOL).
objectiveTo assess the impact of NMS on the QOL of patients with PD in Senegal.
methodsWe conducted a cross-sectional study from January to August 2024. All patients who met the diagnostic criteria for PD and were followed up in the neurology department at the Pikine National Hospital Center were included. NMS were assessed using the Movement Disorders Society-Non-motor Symptoms Scale (MDS-NMS), while QOL was assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39). The Hoehn and Yahr scale was used to determine the disease stage for each patient. The student's t-test was used to compare quantitative variables, and linear regression was used to identify predictive factors for poor QOL.
resultsA total of 52 patients with PD were enrolled. The mean age was 64.6 ± 10 years. The mean MDS-NMS score was 61.8 ± 30.48. The most prevalent NMS were sleep disturbance (98%), constipation (84.6%), and pain (84.6%). The mean PDQ-39 index was 23.45 ± 12.5%. The most affected domains for the QOL were mobility and activities of daily living. There was a significant correlation between the MDS-NMS score and the PDQ-39 index (β = 0.448; P = 0.001). In addition, depression (β = 0.398; P = 0.043) and cognitive impairment (β = 0.355; P = 0.046) were predictive of poor QOL. Patients presenting with depression (p = 0.000), fatigue (p = 0.018), urinary urgency (p = 0.03), and hypersalivation (p = 0.003) had a significantly worse QOL than those who did not.
conclusionIn our cohort, non-motor symptoms, particularly depression and cognitive impairment, were significantly associated with poorer quality of life. Although the confounding effect of motor symptoms was not fully assessed, motor severity, assessed by the Hoehn and Yahr stage, also contributed substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.